<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820170</url>
  </required_header>
  <id_info>
    <org_study_id>08-122</org_study_id>
    <nct_id>NCT00820170</nct_id>
  </id_info>
  <brief_title>Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194</brief_title>
  <official_title>A Phase I-II Study of Dasatinib in Combination With Weekly Paclitaxel for Patients With Metastatic Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find the highest dose of dasatinib that can be safely given
      to a patient when the drug is given in combination with the known anticancer drug paclitaxel.
      Paclitaxel is an established anti-cancer drug, used in the treatment of many cancers, and it
      is an approved treatment for breast cancer. Dasatinib has been approved by the Food and Drug
      Administration for use as a single therapy in another kind of cancer, but its use in breast
      cancer patients, and in combination with paclitaxel is investigational.

      In this study, we will test the safety of dasatinib when given at different dose levels in
      combination with paclitaxel. We want to find out what effects, good and/or bad, it has on the
      patient and on metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I Portion: Maximum Tolerated Dose/MTD of Dasatinib When Administered in Combination With a Fixed Dose of Weekly Paclitaxel.</measure>
    <time_frame>Through completion of Phase I, up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy (Objective Response Rate; ORR; Complete Response (CR) + Partial Response (PR)) of Dasatinib When Administered in Combination With Weekly Paclitaxel at the MTD Established During the Phase I Portion of This Trial.</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival for Phase II Participants</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>Overall Survival for Phase II Participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Adverse Events to Measure Safety and Tolerability of Dasatinib When Administered in Combination With Weekly Paclitaxel.</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>Evaluate adverse events using CTCAE v3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression Free Survival for Phase II Participants</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>Per RECIST criteria, Progression (PD) is defined at least a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Number of Participants With Clinical Benefit According to Tumor Biomarker Data: Assays of VEGFR2</measure>
    <time_frame>8 weeks</time_frame>
    <description>Tumor biomarker data obtained at baseline and after 2 cycles of treatment (8 weeks), will be performed by enzyme-linked immunosorbent assay. Clinical Benefit is defined as the sum of the percentage of participants who achieved CR, PR and stable disease for &gt; 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time To Progression for Phase II Participants</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Number of Participants With Clinical Benefit According to Circulating Tumor Cells (CTC) at Baseline and After 2 Cycles of Treatment (8 Weeks)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Phase II participants only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Exploratory Somatic Gene Mutations Detection in Archived Tumor Samples</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>dasatinib and paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel.
The phase II portion of this trial has a Simon two-stage design to determine the efficacy of dasatinib when administered in combination with paclitaxel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib and Paclitaxel</intervention_name>
    <description>A treatment cycle will consist of 28 days, according to the following schedule:
Dasatinib 120MG PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.
The trial will initially test the combination of weekly paclitaxel and dasatinib given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule, 5 days on and 2 days off, omitting dasatinib the day prior and the day of administration of paclitaxel.</description>
    <arm_group_label>dasatinib and paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male patients with diagnosis of invasive adenocarcinoma of the breast
             confirmed at MSKCC.

          -  For the phase I portion, patients with any ER/PR/HER2 disease status, no longer
             eligible for hormonal therapy or HER2-targeted therapy, will be eligible.

          -  For the phase II portion, there needs to be documentation of negative HER2 (IHC 0-1+
             or FISH/CISH negative) status. Patients with any ER/PR disease status are eligible.

          -  A paraffin-embedded tissue block or unstained slides from prior surgery must be
             available.

          -  Evidence of recurrent or progressive locally advanced or metastatic breast cancer.

        Presence of:

          -  For the phase I portion: at least one evaluable or measurable metastatic lesion ,

          -  For the phase II portion: at least one measurable metastatic lesion according to the
             RECIST criteria which has not been irradiated (i.e. newly arising lesions in
             previously irradiated areas are accepted). Ascites, pleural effusion, and bone
             metastases are not considered measurable. Minimum indicator lesion size: &gt; or = to 10
             mm measured by spiral CT or &gt; or = to 20 mm measured by conventional techniques.

        Prior therapies:

        For the phase I portion: Any number of prior endocrine or biologic therapies is permitted .
        In addition, patients may be untreated in the metastatic setting or have received any
        number of prior cytotoxic regimens.

        For the phase II portion: 0-2 prior therapies for metastatic disease are allowed.

        Prior taxane therapy, either in the adjuvant or in the metastatic setting, either deliver
        weekly, q 2 weeks or q 3 weeks, will be permitted. Prior therapy with bevacizumab will be
        allowed. All previous chemotherapy, radiotherapy and intravenous biphosphonates must have
        been discontinued at least 3 weeks prior to study entry, 3 weeks also for trastuzumab and
        bevacizumab. All acute toxic effects (excluding alopecia) of any prior therapy must have
        resolved to NCI CTC (Version 3) Grade ≤1.

          -  Endocrine therapy with an aromatase inhibitor, SERM (ie, tamoxifen) or fulvestrant is
             permitted, however it must be discontinued before enrolling in the study.

          -  ECOG performance status of 0 or 1.

          -  Age &gt; or = to 18 years old. Adequate Organ Function

          -  Total bilirubin ≤ 1.5 times the institutional Upper Limit of Normal (ULN)

          -  Hepatic enzymes (AST, ALT ) ≤ 2.5 times the institutional ULN

          -  Serum Na, K+, Mg2+, Phosphate and Ca2+≥ Lower Limit of Normal (LLN)

          -  Serum Creatinine ≤ 1.5 time the institutional ULN

          -  Neutrophil count, Platelets, both Grade 0-1

          -  PT (INR) and PTT Grade 0-1, except for patients on Coumadin or low molecular weight
             heparin

          -  Ability to take oral medication (dasatinib must be swallowed whole)

        Concomitant Medications:

          -  Patient agrees to discontinue St. Johns Wort while receiving dasatinib therapy

          -  Patient agrees that IV biphosphonates will be withheld for the first 8 weeks of
             dasatinib therapy due to risk of hypocalcemia. Concomitant Medications, any of the
             following should be considered for exclusion:

        Patient agrees to discontinue QT-prolonging agents strongly associated with Torsades de
        Pointes including: (patients must discontinue drug ≥ 7 days prior to starting dasatinib)
        such as:

          -  quinidine, procainamide, disopyramide

          -  amiodarone, sotalol, ibutilide, dofetilide

          -  erythromycin, clarithromycin

          -  chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide

          -  cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone,
             halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine.

          -  The concomitant use of H2 blockers or proton pump inhibitors with dasatinib is not
             recommended. The use of antacids should be considered in place of H2 blockers or
             proton pump inhibitors in patients receiving dasatinib therapy. If antacid therapy is
             needed, the antacid dose should be administered at least 2 hours prior to or 2 hours
             after the dose of dasatinib.

          -  Patient may not be receiving any potent CYP3A4 inhibitors. These are prohibited
             (patients must discontinue drug ≥7 days prior to starting dasatinib) and include:

          -  itraconazole, ketoconazole, miconazole, coriconazole

          -  amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir

          -  ciprofloxacin, clarithromycin, diclofenac, doxycycline, enoxacin, imatinib, isoniazid

          -  ketamine, nefazodone, nicardipine, propofol, quinidine, telithromycin

        Women of childbearing potential (WOCBP) must have:

          -  A negative serum or urine pregnancy test within 72 hours prior to the start of study
             drug administration

          -  Persons of reproductive potential must agree to use an adequate method of
             contraception throughout treatment and for at least 4 weeks after study drug is
             stopped

          -  Pregnant or nursing women may not participate. Patients of reproductive potential may
             not participate unless they have agreed to use an effective method of contraception
             and to continue contraception for 30 days from the date of the last study drug
             administration. Postmenopausal woman must be amenorrheic for at least 12 months to be
             considered of non-childbearing potential.

          -  Signed written informed consent including a HIPAA form according to institutional
             guidelines.

        Exclusion Criteria:

          -  Life expectancy &lt; 3 months.

          -  Prior severe allergic reaction to paclitaxel therapy.

          -  Presence of new or recurrent pleural effusion which is symptomatic and/or requiring
             medical intervention (NCI CTC Grade 2, 3 or 4).

          -  Completion of previous chemotherapy regimen &lt; 3 weeks prior to the start of study
             treatment.

          -  Prior hormonal therapy must be discontinued prior to treatment start. Biologic therapy
             (eg, bevacizumab, trastuzumab) for the treatment of metastatic disease must be
             discontinued &gt; or = to 3 weeks from the start of protocol treatment.

        Concurrent medical condition which may increase the risk of toxicity.

        Patients may not have any clinically significant cardiovascular disease including the
        following:

          -  myocardial infarction or ventricular tachyarrhythmia within 6 months

          -  prolonged QTc &gt;480 msec (Fridericia correction)

          -  ejection fraction less than institutional normal

          -  major conduction abnormality (unless a cardiac pacemaker is present)

          -  Patients with any cardiopulmonary symptoms of unknown cause (e.g. shortness of breath,
             chest pain, etc.) should be evaluated by a baseline echocardiogram with or without
             stress test as needed in addition to electrocardiogram (EKG) to rule out QTc
             prolongation. The patient may be referred to a cardiologist at the discretion of the
             principal investigator. Patients with underlying cardiopulmonary dysfunction should be
             excluded from the study.

          -  Subjects with hypokalemia or hypomagnesemia if it cannot be corrected prior to
             dasatinib administration

        History of significant bleeding disorder unrelated to cancer, including:

        Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)

          -  Diagnosed acquired bleeding disorder within one year (e.g., acquired antifactor VIII
             antibodies)

          -  Ongoing or recent (≤ 3 months) significant gastrointestinal bleeding Other medical
             condition which in the opinion of the Investigator might confer an unacceptable
             increase in risk.

          -  Patients with symptomatic CNS metastases that remain untreated by radiation therapy
             are excluded from this trial. The presence of asymptomatic brain metastases or brain
             metastases that have been previously irradiated are not grounds for trial exclusion.

          -  History of uncontrolled seizures, central nervous system disorders or psychiatric
             disability judged by the investigator to be clinically significant, precluding
             informed consent, or interfering with compliance of oral drug intake.

          -  Presence of uncontrolled gastrointestinal malabsorption syndrome.

          -  Unwillingness to give written informed consent or unwillingness to participate or
             inability to comply with the protocol for the duration of the study. Willingness and
             ability to comply with scheduled visits, treatment plan, laboratory tests and other
             study procedures are necessary for participation in this clinical trial.

          -  Concurrent radiotherapy is not permitted for disease progression on treatment on
             protocol, but might allowed for pre-existing non-target lesions with approval from the
             principal investigator of the trial.

          -  Patients with &gt; Grade 1 neuropathy will be excluded form this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Fornier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2009</study_first_posted>
  <results_first_submitted>January 25, 2019</results_first_submitted>
  <results_first_submitted_qc>July 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2019</results_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast</keyword>
  <keyword>Cancer</keyword>
  <keyword>DASATINIB</keyword>
  <keyword>TAXOL (PACLITAXEL)</keyword>
  <keyword>08-122</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 15, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT00820170/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 100 mg</title>
          <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 100 mg daily continuously</description>
        </group>
        <group group_id="P2">
          <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 150 mg</title>
          <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 150 mg daily continuously</description>
        </group>
        <group group_id="P3">
          <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 70 mg</title>
          <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 70 mg daily continuously</description>
        </group>
        <group group_id="P4">
          <title>Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg</title>
          <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 120 mg daily continuously</description>
        </group>
        <group group_id="P5">
          <title>Participants Who Did Not Receive Treatment</title>
          <description>Participants did not receive treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The 3 participants treated in the Phase I portion of the study at Paclitaxel 80mg/m2 + Dasatinib 120 mg were included in the group of 40 participants in the Phase II portion of this study.</population>
      <group_list>
        <group group_id="B1">
          <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 100 mg</title>
          <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 100 mg daily continuously</description>
        </group>
        <group group_id="B2">
          <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 150 mg</title>
          <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 150 mg daily continuously</description>
        </group>
        <group group_id="B3">
          <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 70 mg</title>
          <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 70 mg daily continuously</description>
        </group>
        <group group_id="B4">
          <title>Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg</title>
          <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 120 mg daily continuously</description>
        </group>
        <group group_id="B5">
          <title>No Arm Selected</title>
          <description>No Treatment Arm Selected</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="39" upper_limit="67"/>
                    <measurement group_id="B2" value="56" lower_limit="41" upper_limit="74"/>
                    <measurement group_id="B3" value="59" lower_limit="54" upper_limit="62"/>
                    <measurement group_id="B4" value="50.7" lower_limit="30" upper_limit="79"/>
                    <measurement group_id="B5" value="52.5" lower_limit="47" upper_limit="58"/>
                    <measurement group_id="B6" value="51.89" lower_limit="30" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase I Portion: Maximum Tolerated Dose/MTD of Dasatinib When Administered in Combination With a Fixed Dose of Weekly Paclitaxel.</title>
        <time_frame>Through completion of Phase I, up to 1 year</time_frame>
        <population>15 participants were enrolled for the Phase I portion of the study. These 15 participants determined the MTD for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib and Paclitaxel</title>
            <description>The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel.
The phase II portion of this trial has a Simon two-stage design to determine the efficacy of dasatinib when administered in combination with paclitaxel.
Dasatinib and Paclitaxel: A treatment cycle will consist of 28 days, according to the following schedule:
Dasatinib 120MG PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.
The trial will initially test the combination of weekly paclitaxel and dasatinib given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule, 5 days on and 2 days off, omitting dasatinib the day prior and the day of administration of paclitaxel.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I Portion: Maximum Tolerated Dose/MTD of Dasatinib When Administered in Combination With a Fixed Dose of Weekly Paclitaxel.</title>
          <population>15 participants were enrolled for the Phase I portion of the study. These 15 participants determined the MTD for the study.</population>
          <units>mg of dasatinib</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy (Objective Response Rate; ORR; Complete Response (CR) + Partial Response (PR)) of Dasatinib When Administered in Combination With Weekly Paclitaxel at the MTD Established During the Phase I Portion of This Trial.</title>
        <time_frame>Through study completion, up to 2 years</time_frame>
        <population>The 3 participants treated in the Phase I portion of the study at Paclitaxel 80mg/m2 + Dasatinib 120 mg were included in the group of 40 participants in the Phase II portion of this study. Results and data analysis reflect this.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 100 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 100 mg daily continuously</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 150 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 150 mg daily continuously</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 70 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 70 mg daily continuously</description>
          </group>
          <group group_id="O4">
            <title>Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 120 mg daily continuously</description>
          </group>
          <group group_id="O5">
            <title>No Arm Selected</title>
            <description>No Treatment Arm Selected</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy (Objective Response Rate; ORR; Complete Response (CR) + Partial Response (PR)) of Dasatinib When Administered in Combination With Weekly Paclitaxel at the MTD Established During the Phase I Portion of This Trial.</title>
          <population>The 3 participants treated in the Phase I portion of the study at Paclitaxel 80mg/m2 + Dasatinib 120 mg were included in the group of 40 participants in the Phase II portion of this study. Results and data analysis reflect this.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progression of Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Evaluable for Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival for Phase II Participants</title>
        <description>Overall Survival for Phase II Participants</description>
        <time_frame>Through study completion, up to 2 years</time_frame>
        <population>This objective is specific for the Phase II participants</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 100 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 100 mg daily continuously</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 150 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 150 mg daily continuously</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 70 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 70 mg daily continuously</description>
          </group>
          <group group_id="O4">
            <title>Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 120 mg daily continuously</description>
          </group>
          <group group_id="O5">
            <title>No Arm Selected</title>
            <description>No Treatment Arm Selected</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival for Phase II Participants</title>
          <description>Overall Survival for Phase II Participants</description>
          <population>This objective is specific for the Phase II participants</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="20.6" lower_limit="12.9" upper_limit="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Adverse Events to Measure Safety and Tolerability of Dasatinib When Administered in Combination With Weekly Paclitaxel.</title>
        <description>Evaluate adverse events using CTCAE v3</description>
        <time_frame>Through study completion, up to 2 years</time_frame>
        <population>The 3 participants treated in the Phase I portion of the study at Paclitaxel 80mg/m2 + Dasatinib 120 mg were included in the group of 40 participants in the Phase II portion of this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Paclitaxel 80 mg/m2 + Dasatinib 100 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 100 mg daily continuously</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 120 mg daily continuously</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Paclitaxel 80 mg/m2 + Dasatinib 150 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 150 mg daily continuously</description>
          </group>
          <group group_id="O4">
            <title>Paclitaxel 80 mg/m2 + Dasatinib 70 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 70 mg daily continuously</description>
          </group>
          <group group_id="O5">
            <title>No Arm Selected</title>
            <description>No Treatment Arm Selected</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Adverse Events to Measure Safety and Tolerability of Dasatinib When Administered in Combination With Weekly Paclitaxel.</title>
          <description>Evaluate adverse events using CTCAE v3</description>
          <population>The 3 participants treated in the Phase I portion of the study at Paclitaxel 80mg/m2 + Dasatinib 120 mg were included in the group of 40 participants in the Phase II portion of this study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression Free Survival for Phase II Participants</title>
        <description>Per RECIST criteria, Progression (PD) is defined at least a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
        <time_frame>Through study completion, up to 2 years</time_frame>
        <population>This objective is specific for the Phase II participants</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 100 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 100 mg daily continuously</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 150 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 150 mg daily continuously</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 70 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 70 mg daily continuously</description>
          </group>
          <group group_id="O4">
            <title>Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 120 mg daily continuously</description>
          </group>
          <group group_id="O5">
            <title>No Arm Selected</title>
            <description>No Treatment Arm Selected</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression Free Survival for Phase II Participants</title>
          <description>Per RECIST criteria, Progression (PD) is defined at least a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
          <population>This objective is specific for the Phase II participants</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="5.2" lower_limit="2.9" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Number of Participants With Clinical Benefit According to Tumor Biomarker Data: Assays of VEGFR2</title>
        <description>Tumor biomarker data obtained at baseline and after 2 cycles of treatment (8 weeks), will be performed by enzyme-linked immunosorbent assay. Clinical Benefit is defined as the sum of the percentage of participants who achieved CR, PR and stable disease for &gt; 6 months.</description>
        <time_frame>8 weeks</time_frame>
        <population>Phase II participants only</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 100 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 100 mg daily continuously</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 150 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 150 mg daily continuously</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 70 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 70 mg daily continuously</description>
          </group>
          <group group_id="O4">
            <title>Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 120 mg daily continuously</description>
          </group>
          <group group_id="O5">
            <title>No Arm Selected</title>
            <description>No Treatment Arm Selected</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Number of Participants With Clinical Benefit According to Tumor Biomarker Data: Assays of VEGFR2</title>
          <description>Tumor biomarker data obtained at baseline and after 2 cycles of treatment (8 weeks), will be performed by enzyme-linked immunosorbent assay. Clinical Benefit is defined as the sum of the percentage of participants who achieved CR, PR and stable disease for &gt; 6 months.</description>
          <population>Phase II participants only</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Discontinued prior to 1st Assessment</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clinical Benefit, VEGF collected</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Clinical Benefit, VEGF Collected</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clinical Benefit, VEGF Not Collected</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Clinical Benefit, VEGF Not Collected</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time To Progression for Phase II Participants</title>
        <time_frame>Through study completion, up to 2 years</time_frame>
        <population>This objective is specific for the Phase II participants</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 100 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 100 mg daily continuously</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 150 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 150 mg daily continuously</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 70 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 70 mg daily continuously</description>
          </group>
          <group group_id="O4">
            <title>Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 120 mg daily continuously</description>
          </group>
          <group group_id="O5">
            <title>No Arm Selected</title>
            <description>No Treatment Arm Selected</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time To Progression for Phase II Participants</title>
          <population>This objective is specific for the Phase II participants</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="5.84" lower_limit="0" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Number of Participants With Clinical Benefit According to Circulating Tumor Cells (CTC) at Baseline and After 2 Cycles of Treatment (8 Weeks)</title>
        <description>Phase II participants only</description>
        <time_frame>8 weeks</time_frame>
        <population>Phase II participants only</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 100 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 100 mg daily continuously</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 150 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 150 mg daily continuously</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 70 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 70 mg daily continuously</description>
          </group>
          <group group_id="O4">
            <title>Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 120 mg daily continuously</description>
          </group>
          <group group_id="O5">
            <title>No Arm Selected</title>
            <description>No Treatment Arm Selected</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Number of Participants With Clinical Benefit According to Circulating Tumor Cells (CTC) at Baseline and After 2 Cycles of Treatment (8 Weeks)</title>
          <description>Phase II participants only</description>
          <population>Phase II participants only</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Discontinued treatment prior to 1st assessment</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clinical Benefit, CTC Collection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Clinical Benefit, CTC Collection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clinical Benefit, No CTC Collected</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Exploratory Somatic Gene Mutations Detection in Archived Tumor Samples</title>
        <time_frame>2 years</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 100 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 100 mg daily continuously</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 150 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 150 mg daily continuously</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 70 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 70 mg daily continuously</description>
          </group>
          <group group_id="O4">
            <title>Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg</title>
            <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 120 mg daily continuously</description>
          </group>
          <group group_id="O5">
            <title>No Arm Selected</title>
            <description>No Treatment Arm Selected</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Exploratory Somatic Gene Mutations Detection in Archived Tumor Samples</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Phase I: 1 year Phase II: 2 years</time_frame>
      <desc>3 participants treated in the Phase I portion of the study at Paclitaxel 80mg/m2 + Dasatinib 120 mg were included in the group of 40 participants in the Phase II portion of this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 100 mg</title>
          <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 100 mg daily continuously</description>
        </group>
        <group group_id="E2">
          <title>Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 150 mg</title>
          <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 150 mg daily continuously</description>
        </group>
        <group group_id="E3">
          <title>Phast 1: Paclitaxel 80 mg/m2 + Dasatinib 70 mg</title>
          <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 70 mg daily continuously</description>
        </group>
        <group group_id="E4">
          <title>Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg</title>
          <description>Paclitaxel 80 mg/m2 weekly 3/4; Dasatinib 120 mg daily continuously</description>
        </group>
        <group group_id="E5">
          <title>No Arm Selected</title>
          <description>No Treatment Arm Selected</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin decreased/Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Serum phosphate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Heartburn/Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>INR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>White Blood Cells/Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutrophils/Granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Prolonged QTc interval</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cholesterol, high (hypercholestremia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lymphocytes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>PTT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Glucose, high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Phosphate, low (hypophosphatemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Potassium, high (hyperkalemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Potassium, low (hypokalemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Glucose, high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Glucose, low (hypoglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain - Muscle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nail Changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Monica Fornier</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-888-4563</phone>
      <email>fornierm@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

